tiprankstipranks
AbbVie price target raised to $221 from $212 at Guggenheim
The Fly

AbbVie price target raised to $221 from $212 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $221 from $212 and keeps a Buy rating on the shares. The firm is updating its model following the company’s Q3 earnings results last week, stating that AbbVie reported “a solid quarter” with results beating on both sales and quarterly EPS.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App